Has Scott Feitell, DO received payments from drug or device companies?

Yes. Drug and device makers reported $483,841 in general payments to Scott Feitell, DO across 964 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Scott Feitell, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Scott Feitell, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Scott Feitell, DO

Advanced Heart Failure and Transplant Cardiology · Rochester, NYNPI 1770815540

Payments from drug & device makers

$483,841in general payments, 2019–2025

Across 964 payments — averaging $501.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$96K
Pfizer$60K
Actelion Pharmaceuticals US, Inc.$47K
Alnylam Pharmaceuticals Inc.$41K
Novartis$41K
Lexicon Pharmaceuticals, Inc.$33K
plus $166K from 32 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	220	$95,827
Pfizer	40	$60,209
Actelion Pharmaceuticals US, Inc.	234	$47,205
Alnylam Pharmaceuticals Inc.	53	$40,999
Novartis	73	$40,582
Lexicon Pharmaceuticals, Inc.	45	$33,465
Amgen	12	$33,088
AstraZeneca	67	$32,973
Scpharmaceuticals Inc.	34	$31,388
Vifor Pharma, Inc.	20	$21,128
Bridgebio Pharma, Inc.	19	$15,065
Impulse Dynamics (USA) Inc.	16	$10,436
Akcea Therapeutics, Inc.	6	$5,571
Johnson & Johnson	11	$5,026
Sensible Medical Innovations Inc	3	$3,728
Medicure Pharma Inc.	2	$3,000
Bayer	5	$1,448
Cvrx, Inc.	18	$561
Merck	19	$435
Abiomed	7	$311
Boehringer Ingelheim	12	$251
Novo Nordisk	10	$210
Irhythm Technologies, Inc.	6	$167
Getinge USA Sales, LLC	2	$119
Kestra Medical Technology Services, Inc.	4	$112
Atricure, Inc.	3	$78
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	5	$76
E.r. Squibb & Sons, L.L.C.	4	$73
United Therapeutics Corporation	3	$66
Liquidia Technologies, Inc.	2	$60
Kiniksa Pharmaceuticals, Ltd.	2	$34
Boston Scientific	1	$30
Kiniksa Pharmaceuticals International, PLC	1	$25
Daiichi Sankyo Inc.	1	$24
GSK	1	$21
Medtronic	1	$20
Livanova USA, Inc.	1	$18
Esperion Therapeutics, Inc.	1	$13

How this compares

$483,841 in reported general payments places this provider in the 90th percentile of 106 advanced heart failure and transplant cardiology providers in New York.

See all advanced heart failure and transplant cardiology providers in New York →

Medicare billing

Part B allowed, 2024

$52,680

Medicare patients

206

Services billed

1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other advanced heart failure and transplant cardiology in Rochester

Elizabeth LeeRochester$23K
Mathew MaurerNew York$5M
Evelyn HornNew York$2.9M
Johanna ContrerasNew York$1.4M
Parag GoyalNew York$1.1M
Rita JermynRoslyn$993K
James LyonsPoughkeepsie$954K
Nir UrielNew York$884K
Tajinderpal SaraonNew York$618K
Kelly AxsomNew York$502K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →